Compare $NVAX vs $ZBIO | Chartloom

Compare

$NVAX vs $ZBIO

Novavax Inc · Zenas Biopharma Inc

NVAX

Novavax Inc

ZBIO

Zenas Biopharma Inc

Compare $NVAX vs $ZBIO

Comparing Novavax Inc and Zenas Biopharma Inc

NVAXNovavax Inc

ZBIOZenas Biopharma Inc

NVAXNovavax Inc

Market cap

$2.10B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

10.28x

Rev growth (TTM)

-61.6%

YTD performance

78.8%

52W performance

43.3%

FCF yield

-2.0%

ZBIOZenas Biopharma Inc

Market cap

$1.72B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-93.3%

YTD performance

-21.0%

52W performance

5.3%

FCF yield

-16.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

NVAX

ZBIO

Detailed metrics comparison

NVAX

Novavax Inc

ZBIO

Zenas Biopharma Inc

Market Cap

NVAX$2.10B

ZBIO$1.72B

Enterprise Value

NVAX$2.20B

ZBIO$1.91B

Price

NVAX$12.75

ZBIO$27.26

P/E Ratio

NVAXN/A

ZBION/A

P/S Ratio

NVAX5.07x

ZBIO1,720.92x

EV/Sales

NVAX5.32x

ZBIO1,913.10x

EV/EBITDA

NVAX4.05x

ZBIO0.00x

P/B Ratio

NVAX45.86x

ZBIO7.47x

P/FCF Ratio

NVAXN/A

ZBION/A

EV/FCF

NVAX-51.40x

ZBIO-6.57x

PEG Ratio

NVAXN/A

ZBION/A

Forward P/E (NTM)

NVAXN/A

ZBION/A

Forward P/S (NTM)

NVAX10.28x

ZBION/A

Revenue (TTM)

NVAX$414M

ZBIO$1M

Revenue Growth (YoY)

NVAX-61.6%

ZBIO-93.3%

Forward Rev Growth

NVAX-25.1%

ZBIO5296.9%

Gross Margin (TTM)

NVAX79.2%

ZBIO0.0%

Operating Margin (TTM)

NVAX0.0%

ZBIO0.0%

EBITDA Margin (TTM)

NVAX-24.0%

ZBIO-27387.0%

Net Margin (TTM)

NVAX-59.9%

ZBIO-48438.4%

FCF Margin (TTM)

NVAX-10.4%

ZBIO-29097.4%

Net Income (TTM)

NVAX$-248M

ZBIO$-484M

FCF (TTM)

NVAX$-43M

ZBIO$-291M

EPS (TTM)

NVAX-$1.51

ZBIO-$7.67

ROE (TTM)

NVAX283.1%

ZBIO-18968.0%

ROA (TTM)

NVAX-2275.0%

ZBIO-8991.0%

ROIC (TTM)

NVAX40.0%

ZBIO-10131.0%

Cash

NVAX$191M

ZBIO$197M

Debt

NVAX$297M

ZBIO$389M

Net Cash/Debt

NVAX$-106M

ZBIO$-192M

Current Ratio (TTM)

NVAX2.33x

ZBIO9.93x

Quick Ratio (TTM)

NVAX2.23x

ZBIO9.77x

Debt/Equity (TTM)

NVAX6.07x

ZBIO1.57x

Debt/Assets (TTM)

NVAX0.0%

ZBIO0.0%

Interest Coverage (TTM)

NVAXN/A

ZBION/A

Net Debt/EBITDA (TTM)

NVAX0.00x

ZBIO0.00x

Beta

NVAX2.81

ZBIO0.70

52W Performance

NVAX43.3%

ZBIO5.3%

YTD Performance

NVAX78.8%

ZBIO-21.0%

% from 52W High

NVAX-4.7%

ZBIO-38.9%

% from 52W Low

NVAX105.6%

ZBIO101.9%

Asset Turnover (TTM)

NVAX0.38x

ZBIO0.00x

FCF Yield (TTM)

NVAX-2.0%

ZBIO-16.9%

Earnings Yield (TTM)

NVAX-11.8%

ZBIO-28.1%

Dividend Yield (TTM)

NVAXN/A

ZBION/A

Rule of 40

NVAX-72.0

ZBIO-29,190.7

EV/GP/RG

NVAXN/A

ZBION/A

Ticker research

View NVAX research View ZBIO research

Metric	NVAX Novavax Inc	ZBIO Zenas Biopharma Inc
Market & Valuation
Market Cap	$2.10B	$1.72B
Enterprise Value	$2.20B	$1.91B
Price	$12.75	$27.26
P/E Ratio	N/A	N/A
P/S Ratio	5.07x	1,720.92x
EV/Sales	5.32x	1,913.10x
EV/EBITDA	4.05x	0.00x
P/B Ratio	45.86x	7.47x
P/FCF Ratio	N/A	N/A
EV/FCF	-51.40x	-6.57x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	10.28x	N/A
Revenue & Growth
Revenue (TTM)	$414M	$1M
Revenue Growth (YoY)	-61.6%	-93.3%
Forward Rev Growth	-25.1%	5296.9%
Profitability
Gross Margin (TTM)	79.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-24.0%	-27387.0%
Net Margin (TTM)	-59.9%	-48438.4%
FCF Margin (TTM)	-10.4%	-29097.4%
Net Income (TTM)	$-248M	$-484M
FCF (TTM)	$-43M	$-291M
EPS (TTM)	-$1.51	-$7.67
ROE (TTM)	283.1%	-18968.0%
ROA (TTM)	-2275.0%	-8991.0%
ROIC (TTM)	40.0%	-10131.0%
Financial Health
Cash	$191M	$197M
Debt	$297M	$389M
Net Cash/Debt	$-106M	$-192M
Current Ratio (TTM)	2.33x	9.93x
Quick Ratio (TTM)	2.23x	9.77x
Debt/Equity (TTM)	6.07x	1.57x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.81	0.70
52W Performance	43.3%	5.3%
YTD Performance	78.8%	-21.0%
% from 52W High	-4.7%	-38.9%
% from 52W Low	105.6%	101.9%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.00x
FCF Yield (TTM)	-2.0%	-16.9%
Earnings Yield (TTM)	-11.8%	-28.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-72.0	-29,190.7
EV/GP/RG	N/A	N/A
Ticker research	View NVAX research	View ZBIO research

Valuation

P/S Ratio

NVAX

5.07x

ZBIO

1,720.92x

EV/FCF

NVAX

-51.40x

ZBIO

-6.57x

Growth & revenue

Revenue Growth TTM

NVAX

-61.6%

ZBIO

-93.3%

Forward Revenue Growth

ZBIO

5296.9%

NVAX

-25.1%

Profitability & performance

Gross Margin

NVAX

79.2%

ZBIO

0.0%

ROE

NVAX

283.1%

ZBIO

-18968.0%

FCF Yield %

NVAX

-2.0%

ZBIO

-16.9%

52-Week Performance

NVAX

43.3%

ZBIO

5.3%

Detailed metrics comparison

NVAX

Novavax Inc

ZBIO

Zenas Biopharma Inc

Market Cap

NVAX$2.10B

ZBIO$1.72B

Enterprise Value

NVAX$2.20B

ZBIO$1.91B

Price

NVAX$12.75

ZBIO$27.26

P/E Ratio

NVAXN/A

ZBION/A

P/S Ratio

NVAX5.07x

ZBIO1,720.92x

EV/Sales

NVAX5.32x

ZBIO1,913.10x

EV/EBITDA

NVAX4.05x

ZBIO0.00x

P/B Ratio

NVAX45.86x

ZBIO7.47x

P/FCF Ratio

NVAXN/A

ZBION/A

EV/FCF

NVAX-51.40x

ZBIO-6.57x

PEG Ratio

NVAXN/A

ZBION/A

Forward P/E (NTM)

NVAXN/A

ZBION/A

Forward P/S (NTM)

NVAX10.28x

ZBION/A

Revenue (TTM)

NVAX$414M

ZBIO$1M

Revenue Growth (YoY)

NVAX-61.6%

ZBIO-93.3%

Forward Rev Growth

NVAX-25.1%

ZBIO5296.9%

Gross Margin (TTM)

NVAX79.2%

ZBIO0.0%

Operating Margin (TTM)

NVAX0.0%

ZBIO0.0%

EBITDA Margin (TTM)

NVAX-24.0%

ZBIO-27387.0%

Net Margin (TTM)

NVAX-59.9%

ZBIO-48438.4%

FCF Margin (TTM)

NVAX-10.4%

ZBIO-29097.4%

Net Income (TTM)

NVAX$-248M

ZBIO$-484M

FCF (TTM)

NVAX$-43M

ZBIO$-291M

EPS (TTM)

NVAX-$1.51

ZBIO-$7.67

ROE (TTM)

NVAX283.1%

ZBIO-18968.0%

ROA (TTM)

NVAX-2275.0%

ZBIO-8991.0%

ROIC (TTM)

NVAX40.0%

ZBIO-10131.0%

Cash

NVAX$191M

ZBIO$197M

Debt

NVAX$297M

ZBIO$389M

Net Cash/Debt

NVAX$-106M

ZBIO$-192M

Current Ratio (TTM)

NVAX2.33x

ZBIO9.93x

Quick Ratio (TTM)

NVAX2.23x

ZBIO9.77x

Debt/Equity (TTM)

NVAX6.07x

ZBIO1.57x

Debt/Assets (TTM)

NVAX0.0%

ZBIO0.0%

Interest Coverage (TTM)

NVAXN/A

ZBION/A

Net Debt/EBITDA (TTM)

NVAX0.00x

ZBIO0.00x

Beta

NVAX2.81

ZBIO0.70

52W Performance

NVAX43.3%

ZBIO5.3%

YTD Performance

NVAX78.8%

ZBIO-21.0%

% from 52W High

NVAX-4.7%

ZBIO-38.9%

% from 52W Low

NVAX105.6%

ZBIO101.9%

Asset Turnover (TTM)

NVAX0.38x

ZBIO0.00x

FCF Yield (TTM)

NVAX-2.0%

ZBIO-16.9%

Earnings Yield (TTM)

NVAX-11.8%

ZBIO-28.1%

Dividend Yield (TTM)

NVAXN/A

ZBION/A

Rule of 40

NVAX-72.0

ZBIO-29,190.7

EV/GP/RG

NVAXN/A

ZBION/A

Ticker research

View NVAX research View ZBIO research

Metric	NVAX Novavax Inc	ZBIO Zenas Biopharma Inc
Market & Valuation
Market Cap	$2.10B	$1.72B
Enterprise Value	$2.20B	$1.91B
Price	$12.75	$27.26
P/E Ratio	N/A	N/A
P/S Ratio	5.07x	1,720.92x
EV/Sales	5.32x	1,913.10x
EV/EBITDA	4.05x	0.00x
P/B Ratio	45.86x	7.47x
P/FCF Ratio	N/A	N/A
EV/FCF	-51.40x	-6.57x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	10.28x	N/A
Revenue & Growth
Revenue (TTM)	$414M	$1M
Revenue Growth (YoY)	-61.6%	-93.3%
Forward Rev Growth	-25.1%	5296.9%
Profitability
Gross Margin (TTM)	79.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-24.0%	-27387.0%
Net Margin (TTM)	-59.9%	-48438.4%
FCF Margin (TTM)	-10.4%	-29097.4%
Net Income (TTM)	$-248M	$-484M
FCF (TTM)	$-43M	$-291M
EPS (TTM)	-$1.51	-$7.67
ROE (TTM)	283.1%	-18968.0%
ROA (TTM)	-2275.0%	-8991.0%
ROIC (TTM)	40.0%	-10131.0%
Financial Health
Cash	$191M	$197M
Debt	$297M	$389M
Net Cash/Debt	$-106M	$-192M
Current Ratio (TTM)	2.33x	9.93x
Quick Ratio (TTM)	2.23x	9.77x
Debt/Equity (TTM)	6.07x	1.57x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.81	0.70
52W Performance	43.3%	5.3%
YTD Performance	78.8%	-21.0%
% from 52W High	-4.7%	-38.9%
% from 52W Low	105.6%	101.9%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.00x
FCF Yield (TTM)	-2.0%	-16.9%
Earnings Yield (TTM)	-11.8%	-28.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-72.0	-29,190.7
EV/GP/RG	N/A	N/A
Ticker research	View NVAX research	View ZBIO research